Search

Your search keyword '"Calcaterra, Ilenia Lorenza"' showing total 3 results
Start Over Author "Calcaterra, Ilenia Lorenza" Publisher mdpi ag
3 results on '"Calcaterra, Ilenia Lorenza"'

1. Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target

Author

Ambrosino, Pasquale, primary, Calcaterra, Ilenia Lorenza, additional, Mosella, Marco, additional, Formisano, Roberto, additional, D’Anna, Silvestro Ennio, additional, Bachetti, Tiziana, additional, Marcuccio, Giuseppina, additional, Galloway, Brurya, additional, Mancini, Francesco Paolo, additional, Papa, Antimo, additional, Motta, Andrea, additional, Di Minno, Matteo Nicola Dario, additional, and Maniscalco, Mauro, additional

Published
2022
Full Text
View/download PDF

2. Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target

Author

Pasquale Ambrosino, Ilenia Lorenza Calcaterra, Marco Mosella, Roberto Formisano, Silvestro Ennio D’Anna, Tiziana Bachetti, Giuseppina Marcuccio, Brurya Galloway, Francesco Paolo Mancini, Antimo Papa, Andrea Motta, Matteo Nicola Dario Di Minno, Mauro Maniscalco, Ambrosino, Pasquale, Calcaterra, Ilenia Lorenza, Mosella, Marco, Formisano, Roberto, D'Anna, Silvestro Ennio, Bachetti, Tiziana, Marcuccio, Giuseppina, Galloway, Brurya, Mancini, Francesco Paolo, Papa, Antimo, Motta, Andrea, Di Minno, Matteo Nicola Dario, and Maniscalco, Mauro

Subjects
endothelial function, exercise, occupational medicine, outcome, COVID-19, heart failure, Medicine (miscellaneous), arginine, chronic disease, General Biochemistry, Genetics and Molecular Biology, chronic obstructive pulmonary disease, rehabilitation
Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a worldwide emergency, until the declaration of the pandemic in March 2020. SARS-CoV-2 could be responsible for coronavirus disease 2019 (COVID-19), which goes from a flu-like illness to a potentially fatal condition that needs intensive care. Furthermore, the persistence of functional disability and long-term cardiovascular sequelae in COVID-19 survivors suggests that convalescent patients may suffer from post-acute COVID-19 syndrome, requiring long-term care and personalized rehabilitation. However, the pathophysiology of acute and post-acute manifestations of COVID-19 is still under study, as a better comprehension of these mechanisms would ensure more effective personalized therapies. To date, mounting evidence suggests a crucial endothelial contribution to the clinical manifestations of COVID-19, as endothelial cells appear to be a direct or indirect preferential target of the virus. Thus, the dysregulation of many of the homeostatic pathways of the endothelium has emerged as a hallmark of severity in COVID-19. The aim of this review is to summarize the pathophysiology of endothelial dysfunction in COVID-19, with a focus on personalized pharmacological and rehabilitation strategies targeting endothelial dysfunction as an attractive therapeutic option in this clinical setting.

Published
2022
Full Text
View/download PDF

3. Assessment of Platelet Aggregation and Thrombin Generation in Patients with Familial Chylomicronemia Syndrome Treated with Volanesorsen: A Cross-Sectional Study.

Author

Calcaterra IL, Santoro R, Vitelli N, Cirillo F, D'Errico G, Guerrino C, Cardiero G, Di Taranto MD, Fortunato G, Iannuzzo G, and Di Minno MND

Abstract

Background: The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat Familial Chylomicronemia Syndrome (FCS). Cases of decreased platelet count are reported among patients treated with volanesorsen. The aim of the study was to evaluate platelet function and thrombin generation (TG) assessment in FCS patients receiving volanesorsen. We performed a cross-sectional study on FCS patients treated with volanesorsen., Methods: Changes in platelet count PLC were assessed from baseline to Tw12 and Tw36. To assess TG, samples were processed by CAT (with PPP-reagent LOW). The results were expressed by the thrombogram graphic (thrombin variation over time); LagTime; endogenous thrombin potential (ETP); peak; time to reach peak (ttpeak), StartTail and Velocity Index. Platelet aggregation was assessed by testing different agonists using the turbidimetry method., Results: Four FCS patients and four matched healthy controls were included in the present study. Changes in PLC were 30% at Tw12 and 34% at Tw36. Thrombin generation results showed values in the normal range (for patients and controls, respectively, LagTime:10.42 ± 4.40 and 9.25 ± 0.99; ttPeak:14.33 ± 4.01 and 13.10 ± 0.67; StartTail: 32.13 ± 3.54 and 29.46 ± 1.69; Velocity Index: 20.21 ± 3.63 and 33.05 ± 13.21; ETP: 599.80 ± 73.47 and 900.2 ± 210.99; peak value: 76.84 ± 1.07 and 123.30 ± 39.45) and no significant difference between cases and controls. Platelet aggregation test showed values in range, with no significant difference compared to healthy controls., Conclusions: Our study showed for the first time that no significant changes in general hemostasis assessed by TG and in platelet function were observed in FCS patients receiving volanesorsen.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results